Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 13/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL164820 | 0.91 | HTR2A (0.43) | DGAT1CNR1CSF1RHTR2AHTR2C | |
| SCHEMBL162780 | 0.89 | DGAT1 (0.61) | DGAT1CNR1SMN1; SMN2 | |
| SCHEMBL159539 | 0.88 | DGAT1 (0.57) | DGAT1CSF1RTRPV1ALDH1A1 | |
| SCHEMBL15022225 | 0.88 | NTRK1 (0.41) | DGAT1CNR1CSF1RTRPV1ALDH1A1 | |
| SCHEMBL162826 | 0.86 | DGAT1 (0.55) | DGAT1CSF1RTRPV1NTRK1 | |
| SCHEMBL161415 | 0.86 | DGAT1 (0.58) | DGAT1CNR1SMN1; SMN2 | |
| SCHEMBL162338 | 0.86 | DGAT1 (0.54) | DGAT1CNR1TRPV1 | |
| SCHEMBL174099 | 0.85 | DGAT1 (0.53) | DGAT1CNR1CSF1RTRPV1 | |
| SCHEMBL161374 | 0.84 | DGAT1 (0.58) | DGAT1CNR1ALDH1A1 | |
| SCHEMBL163541 | 0.83 | DGAT1 (0.61) | DGAT1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | claimed |
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885CNR1 946/4885CSF1R 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.